Resource Logo
HIV i-Base

FDA warning of drug interactions between boceprevir and some HIV protease inhibitors


The US FDA have notified health care professional and patients that drug interactions between boceprevir and certain ritonavir- boosted HIV protease inhibitors (atazanavir, lopinavir and darunavir) can significantly reduce the effectiveness of these drugs when used together. [1]

Merck, the manufacturer’s of boceprevir also issued a drug warning giving the pharmacokinetic data and the recommendation that “coadministering boceprevir and ritonavir-boosted PIs is not recommended”. [2]

Source: FDA list serve


  1. FDA warning. Victrelis (boceprevir) and ritonavir-boosted Human Immunodeficiency Virus (HIV) protease inhibitor drugs: drug safety communication – drug interactions, (9 February 2012).
  2. Merck. Dear Healthcare Professional letter. Results of pharmacokinetic study in healthy volunteers given VICTRELIS (boceprevir) and ritonavir-boosted HIV protease inhibitors may indicate clinically significant drug interactions for patients coinfected with chronic hepatitis C and HIV. (6 February 2012).

Links to external websites are current at time of posting but not maintained.


Copyright © 2012 -HIV i-Base, Publisher. All rights reserved to I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7410 8488 F: +44 (0) 20 7410 8489 I-BASE HIV Treatment

Information in this article was accurate in April 10, 2012. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.